cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Verve Therapeutics Inc
6 own
4 watching
Current Price
$0
$0.18
(0.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,088.17M
52-Week High
52-Week High
43
52-Week Low
52-Week Low
10.7
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,088.17M
icon52-Week High43
icon52-Week Low10.7
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Verve Therapeutics Inc do?
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Verve Therapeutics Inc make?
News & Events about Verve Therapeutics Inc.
Ticker Report
1month ago
Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV Get Rating) by 58.4% during the 4th quarter, according to its most recent disclosure with the Securities Exchange Commission. The institutional investor owned 1,228,447 shares of the ...
Globe Newswire
3 months ago
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data to be Presented During an Oral Presentation at the2023 American College of Cardiologys Annual ...
PR Newswire
5 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023...
Globe Newswire
5 months ago
NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. (Verve or the Company) (NASDAQ: VERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation...
PR Newswire
5 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Dec. 26, 2022 NEW YORK, Dec. 26, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Verve Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Verve Therapeutics Inc shares?
plus_minus_icon
How can I buy Verve Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Verve Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Verve Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Verve Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Verve Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Verve Therapeutics Inc?
plus_minus_icon
What percentage is Verve Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Verve Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.18
(0.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00